John P. Ford
41Patents
11h-index
36Co-inventors
75Inventor score
Filing activity: Jul 25, 1984 → Nov 10, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7456187B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | Human Necessities | 33 | Expired |
| US9286443B2 | Systems and methods for data aggregation and prioritization | Physics | 27 | Active |
| US4617102A | Process and apparatus for purifying and concentrating DNA from crude mixtures containing DNA | Performing Operations; Transporting | 27 | Expired |
| US4794075A | Method for locating and purifying DNA containing single base mismatches | Emerging Cross-Sectional Technologies | 23 | Expired |
| US4895955A | Non-radioactive carbodiimide precursor to nucleic acid probes | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6979688B2 | Treatment method against side-effects of chemotherapy | Human Necessities | 17 | Expired |
| US8022076B2 | Substituted thieno[2,3-d]pyrimidines as potassium channel inhibitors | Chemistry; Metallurgy | 16 | Expired |
| US6995165B2 | Methods, compositions, and kits for organ protection during systemic anticancer therapy | Human Necessities | 14 | Expired |
| US4775745A | Diazonium compounds useful as components for nucleic acid probes | Emerging Cross-Sectional Technologies | 13 | Expired |
| US7368456B2 | Methods, compositions, and kits for organ protection during systemic anticancer therapy | Human Necessities | 12 | Expired |
| US7662829B2 | Methods, compositions, and kits for organ protection during systemic anticancer therapy | Human Necessities | 11 | Active |
| US9249155B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | Human Necessities | 11 | Active |
| US4750982A | Process and apparatus for purifying and concentrating DNA from crude mixtures containing DNA | Performing Operations; Transporting | 9 | Expired |
| US7816366B2 | Compositions and methods for treating and preventing dermatoses | Human Necessities | 8 | Active |
| US8258147B2 | Compositions and methods for treating and preventing dermatoses | Human Necessities | 7 | Active |
| US7812030B2 | Methods, compositions, and kits for organ protection during systemic anticancer therapy | Human Necessities | 7 | Active |
| US8653090B2 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | Human Necessities | 7 | Active |
| US9119855B2 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | Human Necessities | 6 | Active |
| US9084788B2 | Compositions and methods for treating and preventing dermatoses | Human Necessities | 6 | Active |
| US8489544B2 | System and method for prioritization and display of aggregated data | Physics | 6 | Active |
| US10300059B2 | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | Human Necessities | 6 | Active |
| US10736557B2 | Methods and magnetic imaging devices to inventory human brain cortical function | Physics | 5 | Active |
| US11013742B2 | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | Human Necessities | 4 | Active |
| US4721668A | Pre-electrophoretic nucleic acid hybridization | Chemistry; Metallurgy | 4 | Expired |
| US10653692B2 | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | Human Necessities | 4 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.